Eintrag weiter verarbeiten
Alternated intra‐arterial and intravitreal chemotherapy: successes and failures of advanced intraocular retinoblastoma treated without systemic chemotherapy
Gespeichert in:
| Zeitschriftentitel: | Acta Ophthalmologica |
|---|---|
| Personen und Körperschaften: | , , |
| In: | Acta Ophthalmologica, 95, 2017, S259 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| Zusammenfassung: | <jats:sec><jats:title>Purpose</jats:title><jats:p>To report the efficacy of combined intravitreal chemotherapy (<jats:styled-content style="fixed-case">IV</jats:styled-content>iC) and intra‐arterial chemotherapy (<jats:styled-content style="fixed-case">IAC</jats:styled-content>) for the treatment of advanced stage retinoblastoma.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The medical records of twenty patients affected by unilateral advanced retinoblastoma (Reese‐Ellsworth stage Vb/D of <jats:styled-content style="fixed-case">ABC</jats:styled-content> classification). After clinical and ophthalmoscopic evaluation, they underwent <jats:styled-content style="fixed-case">MRI</jats:styled-content> to exclude local and <jats:styled-content style="fixed-case">CNS</jats:styled-content> dissemination. The <jats:styled-content style="fixed-case">IAC</jats:styled-content> was given to treat retinal masses and intravitreal injections to treat vitreous seeding. Patients had received two cycles (six infusions) of <jats:styled-content style="fixed-case">IAC</jats:styled-content>, and from six up to ten melphalan injections into the vitreous, with an interval of 7–10 days between them.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>All patients underwent to bimonthly <jats:styled-content style="fixed-case">MRI</jats:styled-content> examination, during treatment and every 3 months for 1 year after last injection, to exclude orbital dissemination. Successful control (57.8%) of tumor masses and vitreous seeds was achieved in all cases at 12 up to 60 months follow‐up. No permanent complications have been reported. Transient omplications disappeared throughout the months. No intraocular or orbital tumor recurrence or retinoblastoma metastases were observed.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Sequential <jats:styled-content style="fixed-case">IAC</jats:styled-content> and intravitreal melphalan for advanced retinoblastoma is a good tool to provide retinal and vitreous seed control.</jats:p></jats:sec> |
|---|---|
| ISSN: |
1755-375X
1755-3768 |
| DOI: | 10.1111/j.1755-3768.2017.01191 |